Methylation of O6- methylguanine -DNA transferase gene promoter in bladder cancer and its clinical significance
LIU Xiaoli1 SHAN Xiaohui2 WANG Taoxia1 FENG Shuning1 WANG Xiaoying1 DUAN Xiaoting1 LI Guiying1
1.Department of Nephrology, Affliated Hospital of Hebei University of Engineering, Hebei Province, Handan 056002, China;
2.Department of Neurology, the First Hospital of Yongnian District Handan, Hebei Province, Handan 057150, China
Abstract：Objective To investigate the methylation of O6-methyl guanine-DNA methyl transferase (MGMT) gene promoter in bladder cancer was studied. Methods Ninety-three patients cases of bladder cancer patients admitted to the Affiliated Hospital of Hebei University of technology from January 2010 to January 2012 and treated with surgical resection were selected. Forty-seven cases of bladder cancer patients Admitted to the Hospital during the same period and confirmed to have no bladder tumor by cystoscopy were selected as the control group. Methylation of MGMT gene in bladder cancer and normal bladder mucosa were detected by methylation specific polymerase chain reaction (PCR). The correlation between MGMT methylation and clinical-pathological characteristics was statistically analyzed, and Kaplan-Meier was used to analyze the correlation between MGMT methylation and patient prognosis. Results The relative methylation of MGMT in bladder cancer tissues was significantly higher than that in normal bladder tissues, and the difference was statistically significant (P ＜ 0.01). MGMT methylation was correlated with staging and grading (all P ＜ 0.01), but not with age, gender, tumor size, number, morphology and recurrence frequency (all P ＞ 0.05), Kaplan-Meier survival analysis found that the 5-year overall survival rate of the methylated group was significantly lower than that of the non-methylated group (all P ＞ 0.05). Conclusion The methylation level of MGMT gene was significantly increased in bladder cancer tissue, and MGMT methylation was related to tumor stage, grade and poor prognosis, which could be used as a molecular marker for the diagnosis and prognosis of bladder cancer and worthy of clinical attention.
刘晓丽1 单晓辉2 王桃霞1 冯淑宁1 王晓英1 段小婷1 李桂英1. 膀胱癌O6-甲基鸟嘌呤-DNA转移酶基因启动子甲基化及其临床意义[J]. 中国医药导报, 2019, 16(8): 22-25.
LIU Xiaoli1 SHAN Xiaohui2 WANG Taoxia1 FENG Shuning1 WANG Xiaoying1 DUAN Xiaoting1 LI Guiying1. Methylation of O6- methylguanine -DNA transferase gene promoter in bladder cancer and its clinical significance. 中国医药导报, 2019, 16(8): 22-25.
[1] 韩苏军，张思维，陈万青，等.中国膀胱癌发病现状及流行趋势分析[J].癌症进展，2013，11（1）：89-95.
[2] Audenet F，Attalla K，Sfakianos JP，et al. The evolution of bladder cancer genomics：What have we learned and how can we useit [J]. Urol Oncol，2018，21：1074-1078.
[3] Gee JR，Saltzstein DR，Kim K，et al. A Phase II Randomized，Double-blind，Presurgical Trial of Polyphenon E in BladderCancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers [J]. Cancer Prev Res，2017， 10（5）：298-307.
[4] PhéV，Cussenot O，Rouprêt M，et al. Interest of methylated genes as biomarkers in urothelial cell carcinomas of theurinary tract [J]. BJU Int，2009，104（7）：896-901.
[5] Sobin LH，Wittekind C. TNM classification of malignant tumours. International Union Against Cancer（UICC），ed 6 [R]. New York：Wiley-Liss，2002.
[6] Binabaj MM，Bahrami A，ShahidSales S，et al. The prognostic value of MGMT promoter methylation in glioblastoma：A meta-analysis of clinical trials [J]. J Cell Physiol，2018，233（1）：378-386.
[7] Chen C，Hua H，Han C，et al. Prognosis value of MGMT promoter methylation for patients with lung cancer：a meta-analysis [J]. Int J Clin Exp Pathol，2015，8（9）：11560-11564.
[8] De Maglio G，Casagrande M，Guardascione M，et al. MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primary tumors [J]. Future Oncol，2015，11（8）：1201-1209.
[9] Jahed M，Ebadi N，Mivehchi M，et al. MGMT hypermethylation and BCL-2 overexpression associated with superficial bladder cancer and recurrence [J]. Cancer Biomark，2016，16（4）：627-632.
[10] Bilgrami SM，Qureshi SA，Pervez S，et al. Promoter hypermethylation of tumor suppressor genes correlates with tumor gradeand invasiveness in patients with urothelial bladder cancer [J]. Springerplus，2014，3：178.
[11] Brait M，Banerjee M，Maldonado L，et al. Promoter methylation of MCAM，ERαand ERβin rum of early stage prostate cancerpatient [J]. Oncotarget，2017，8（9）：15431-15440.
[12] Ricceri F，Guarrera S，Sacerdote C，et al. ERCC1 haplotypes modify bladder cancer risk：a case-control study [J]. DNA Repair（Amst），2010，9（2）：191-200.
[13] Jarmalaite S，Jankevicius F，Kurgonaite K. Promoter hypermethylation in tumour suppressor genes shows association with stage，grade and invasiveness of bladder cancer [J]. Oncology，2008，75（3/4）：145-151.
[14] Sacristan R，Gonzalez C，Fernández-Gómez JM，et al. Molecular classification of non-muscle-invasive bladder cancer （pTa low-grade，pT1 low-grade，and pT1 high-grade subgroups） using methylation of tumor-suppressor genes [J]. J Mol Diagn，2014，16（5）：564-572.
[15] He YT，Li DJ，Liang D，et al. Incidence and mortality of bladder cancer in China，2014 [J]. Chin J Oncol，2018， 40（9）：647-652.
[16] Kim YJ，Kim WJ. Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer? [J]. Investig Clin Urol，2016，57（1）：S77-S88.
[17] Volanis D，Papadopoulos G，Doumas K，et al. Molecular mechanisms in urinary bladder carcinogenesis [J]. J BUON，2011，16（4）：589-601.
[18] Zhang J，Zhu Y，Wang Y，et al. Prognostic and Predictive Value of O6-methylguanine Methyltransferase for Chem-otherapy in Patients with Muscle-Invasive Bladder Cancer [J]. Ann Surg Oncol，2018，25（1）：342-348.
[19] Jahed M，Ebadi N，Mivehchi M，et al. MGMT hypermethylation and BCL-2 overexpression associated with superficial bladder cancer and recurrence [J]. Cancer Biomark，2016，16（4）：627-632.
[20] Andrés G，Ashour N，Sánchez-Chapado M，et al. The study of DNA methylation in urological cancer：present and future [J]. Actas Urol Esp，2013，37（6）：368-375.
2019, Vol. 16 
京公网安备 11010502046598号